DBV Technologies S.A. (DBVT)
NasdaqCM · USD · Healthcare · Biotechnology
$9.98 (+2.36%) as of
Key statistics
- Market cap
- 627.23M
- Forward P/E
- -20.47
- EPS (TTM)
- -3.50
- Dividend yield
- 0.00%
- 52-week range
- 8.63 – 26.18
- Beta
- -0.24
- Revenue (TTM)
- 5.04M
- Profit margin
- 0.00%
- Analyst target
- $38.42
- Volume
- 214.83k
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Châtillon, France
- Employees
- 170
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.